{"id":32581,"date":"2025-04-28T12:45:34","date_gmt":"2025-04-28T04:45:34","guid":{"rendered":"https:\/\/flcube.com\/?p=32581"},"modified":"2025-04-28T12:45:35","modified_gmt":"2025-04-28T04:45:35","slug":"pfizers-inlyta-receives-nmpa-approval-for-first-line-renal-cell-carcinoma-combination-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32581","title":{"rendered":"Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy"},"content":{"rendered":"\n

US giant Pfizer Inc. (NYSE: PFE<\/a>) announced last week that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its drug Inlyta (axitinib). The approval authorizes Inlyta for use in combination with toripalimab as a first-line treatment for moderate to high-risk unresectable or metastatic renal cell carcinoma (RCC). This marks the first and only first-line targeted combination immunotherapy for RCC available in China.<\/p>\n\n\n\n

Basis for Approval<\/strong>
The approval was based on positive results from the pivotal Phase III RENOTORCH study conducted in patients with advanced RCC in China. This study provided the necessary evidence to support the efficacy and safety of the combination therapy.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval…<\/p>\n","protected":false},"author":1,"featured_media":32582,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,29,863,309,15,33],"class_list":["post-32581","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-combination-therapy","tag-nyse-pfe","tag-pfizer","tag-product-approvals","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"\nPfizer's Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval from China's National Medical Products Administration (NMPA) for its drug Inlyta (axitinib). The approval authorizes Inlyta for use in combination with toripalimab as a first-line treatment for moderate to high-risk unresectable or metastatic renal cell carcinoma (RCC). This marks the first and only first-line targeted combination immunotherapy for RCC available in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32581\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer's Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy\" \/>\n<meta property=\"og:description\" content=\"US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval from China's National Medical Products Administration (NMPA) for its drug Inlyta (axitinib). The approval authorizes Inlyta for use in combination with toripalimab as a first-line treatment for moderate to high-risk unresectable or metastatic renal cell carcinoma (RCC). This marks the first and only first-line targeted combination immunotherapy for RCC available in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32581\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-28T04:45:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-28T04:45:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2806.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32581#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32581\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy\",\"datePublished\":\"2025-04-28T04:45:34+00:00\",\"dateModified\":\"2025-04-28T04:45:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32581\"},\"wordCount\":126,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32581#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2806.webp\",\"keywords\":[\"Cancer\",\"Combination therapy\",\"NYSE: PFE\",\"Pfizer\",\"Product approvals\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32581#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32581\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32581\",\"name\":\"Pfizer's Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32581#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32581#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2806.webp\",\"datePublished\":\"2025-04-28T04:45:34+00:00\",\"dateModified\":\"2025-04-28T04:45:35+00:00\",\"description\":\"US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval from China's National Medical Products Administration (NMPA) for its drug Inlyta (axitinib). The approval authorizes Inlyta for use in combination with toripalimab as a first-line treatment for moderate to high-risk unresectable or metastatic renal cell carcinoma (RCC). This marks the first and only first-line targeted combination immunotherapy for RCC available in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32581#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32581\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32581#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2806.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2806.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer's Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32581#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer's Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy - Insight, China's Pharmaceutical Industry","description":"US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval from China's National Medical Products Administration (NMPA) for its drug Inlyta (axitinib). The approval authorizes Inlyta for use in combination with toripalimab as a first-line treatment for moderate to high-risk unresectable or metastatic renal cell carcinoma (RCC). This marks the first and only first-line targeted combination immunotherapy for RCC available in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32581","og_locale":"en_US","og_type":"article","og_title":"Pfizer's Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy","og_description":"US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval from China's National Medical Products Administration (NMPA) for its drug Inlyta (axitinib). The approval authorizes Inlyta for use in combination with toripalimab as a first-line treatment for moderate to high-risk unresectable or metastatic renal cell carcinoma (RCC). This marks the first and only first-line targeted combination immunotherapy for RCC available in China.","og_url":"https:\/\/flcube.com\/?p=32581","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-28T04:45:34+00:00","article_modified_time":"2025-04-28T04:45:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2806.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32581#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32581"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy","datePublished":"2025-04-28T04:45:34+00:00","dateModified":"2025-04-28T04:45:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32581"},"wordCount":126,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32581#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2806.webp","keywords":["Cancer","Combination therapy","NYSE: PFE","Pfizer","Product approvals","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32581#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32581","url":"https:\/\/flcube.com\/?p=32581","name":"Pfizer's Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32581#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32581#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2806.webp","datePublished":"2025-04-28T04:45:34+00:00","dateModified":"2025-04-28T04:45:35+00:00","description":"US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval from China's National Medical Products Administration (NMPA) for its drug Inlyta (axitinib). The approval authorizes Inlyta for use in combination with toripalimab as a first-line treatment for moderate to high-risk unresectable or metastatic renal cell carcinoma (RCC). This marks the first and only first-line targeted combination immunotherapy for RCC available in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32581#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32581"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32581#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2806.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2806.webp","width":1080,"height":608,"caption":"Pfizer's Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32581#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2806.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32581"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32581\/revisions"}],"predecessor-version":[{"id":32583,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32581\/revisions\/32583"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32582"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}